London, UK; Brentwood, TN; 3 June 2008 - Protherics PLC (“Protherics” or the “Company”), the international biopharmaceutical company focused on critical care and cancer, announces that today, in accordance with paragraph 3.1.2 of the FSA Disclosure and Transparency Rules, the Company received notification of the following dealings in the Ordinary share capital of the Company (Ordinary 2p Shares) by Directors and other Persons Discharging Managerial Responsibility (PDMRs), which took place on 3 June 2008:
